News ACC25: Mineralys' uncontrolled hypertension drug aces trial Mineralys looks odds on to become the first drug developer to bring an aldosterone synthase inhibitor to market for uncontrolled hypertension.
News Alphabet's Isomorphic raises $600m for AI drug discovery Isomorphic Labs has raised a whopping $600 million to refine its artificial intelligence-powered drug discovery engine and advance its pipeline.
News ACC25: Ozempic shows its value in PAD Novo Nordisk's Ozempic has been shown to improve walking distance in people with diabetes and peripheral artery disease in the STRIDE trial.
News ACC25: Positive results with Lilly's Lp(a)-lowering drug Eli Lilly's lepodisiran has been shown to reduce Lp(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial.
News Industry alarm as FDA's CBER head Peter Marks resigns Industry organisations are alarmed by the resignation of senior FDA official Peter Marks, citing "misinformation and lies" by HHS Secretary Kennedy.
News MSD says subcutaneous Keytruda matches IV form A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.